结直肠癌 (CRC) 的治疗极其复杂，生存率根据诊断时疾病的阶段而有所不同。新辅助放化疗（NACRT）是局部晚期直肠癌（LARC）的常规治疗方法；本研究收集并分析了126例LARC患者的临床资料，并利用GEO数据库以及Western blotting和Real-2等体内外实验进行了相关验证。时间定量PCR、免疫组织化学、免疫荧光、克隆细胞存活测定和裸鼠异种移植模型。在接受新辅助放疗（NART）治疗的LARC患者中，恶性组织中较高的ZNF281表达与较差的预后和较轻的程度相关。肿瘤消退。细胞和小鼠实验表明，ZNF281减少了X射线对小鼠CRC细胞和肿瘤的损伤。我们发现ZNF281的表达可以预测CRC细胞的放射反应，并提示接受新辅助治疗的LARC患者的预后放射治疗。

The treatment of Colorectal cancer (CRC) is extremely complex and survival rates vary depending on the stage of the disease at the time of diagnosis. Neoadjuvant chemoradiotherapy (NACRT), is the conventional treatment for locally advanced rectal cancer (LARC); however, the resistance to chemoradiotherapy in LARC is difficult to predict.In this study, clinical data of 126 LARC patients were collected and analyzed, and relevant validation was performed using GEO database and in vitro and in vivo experiments, including Western blotting and Real-time quantitative PCR, immunohistochemistry, immunofluorescence, clonogenic cell survival assays, and nude-mouse xenograft models.In patients with LARC who were treated with neoadjuvant radiotherapy (NART), higher ZNF281 expression in malignant tissue was associated with a poorer prognosis and lesser degree of tumor regression. Cell and mouse experiments have shown that ZNF281 reduces the damage caused by X-rays to CRC cells and tumors grown in mice.We found that the expression of ZNF281 predicted the radiation response of CRC cells and suggested the prognosis of patients with LARC who received neoadjuvant radiation therapy.